BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed ELDN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:3636e18fe3107bd81b6a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:ELDN P1/P2 readout (est.): Safety\, Pharmacokinetics\, and Efficacy
  of AT 1501 in Patients Undergoing Kidney Transplant
DESCRIPTION:Safety\, Pharmacokinetics\, and Efficacy of AT 1501 in Patients
  Undergoing Kidney Transplant\nNCT05027906 | PHASE1/PHASE2 | RECRUITING | 
 sponsor: Eledon Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nDate precision: month (shown on the f
 irst day)\nTicker ELDN (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT05027906\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05027906
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
